Publication Name	World Journal of Diabetes
Manuscript ID	22359
Country	United Kingdom

Received	2015-08-27 08:57
Peer-Review Started	2015-08-31 09:25
To Make the First Decision	2015-10-08 16:17
Return for Revision	2015-10-19 01:02
Revised	2015-10-30 00:40
Second Decision	2016-01-14 17:50
Accepted by Journal Editor-in-Chief	2016-01-17 21:47
Accepted by Executive Editor-in-Chief	2016-01-22 16:17
Articles in Press	2016-01-22 16:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-03-01 11:19
Publish the Manuscript Online	2016-03-04 10:55

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Use of fibrates in the metabolic syndrome: A review
Manuscript Source	Invited Manuscript
All Author List	Kate E Shipman, Richard C Strange and Sudarshan Ramachandran
Funding Agency and Grant Number
Corresponding Author	Sudarshan Ramachandran, PhD, FRCPath, Professor, Department of Clinical Biochemistry, Heart of England NHS Foundation Trust, Good Hope Hospital, Rectory Road, Sutton Coldfield, West Midlands B75 7RR, United Kingdom. sud.ramachandran@heartofengland.nhs.uk
Key Words	Fibrates; Metabolic syndrome; Paradoxical high density lipoprotein cholesterol decrease; High density lipoprotein cholesterol; Cardiovascular disease; Peroxisome proliferator-activated receptor; Randomised control trial; Triglycerides
Core Tip	Atherogenic dyslipidaemia is characterised by low high density lipoprotein cholesterol (HDL-C) and raised triglycerides, this pattern being associated with adverse cardiovascular risk. The fibrate class of drugs has been shown to both elevate HDL-C and reduce triglyceride concentrations. Despite several randomised control trials the data remain conflicting in regards to the use of fibrates in cardiovascular disease management. Our objective is to consolidate and summarise the literature to clarify the current evidence base.
Publish Date	2016-03-04 10:55
Citation	Shipman KE, Strange RC, Ramachandran S. Use of fibrates in the metabolic syndrome: A review. World J Diabetes 2016; 7(5): 74-88
URL	http://www.wjgnet.com/1948-9358/full/v7/i5/74.htm
DOI	http://dx.doi.org/10.4239/wjd.v7.i5.74

Full Article (PDF)	WJD-7-74.pdf
Full Article (Word)	WJD-7-74.doc
Manuscript File	22359-Review.docx
Answering Reviewers	22359-Answering reviewers.pdf
Audio Core Tip	22359-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	22359-Conflict-of-interest statement.pdf
Copyright License Agreement	22359-Copyright assignment.pdf
Peer-review Report	22359-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	22359-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	22359-Scientific misconduct check.pdf
Scientific Editor Work List	22359-Scientific editor work list.pdf